Aspirin adherence during high-risk pregnancies, a questionnaire study

•21.4-46.3% of women is non-adherent to aspirin in a high-risk pregnancy.•We found no relation between non-adherence and patient characteristics.•The non-adherence rates in this study are comparable with non-pregnant patients.

ObjectiveAspirin reduces the risk of recurrent hypertensive disorders of pregnancy (HD) and fetal growth restriction (FGR). This study examined the non-adherence rates of aspirin in women with high-risk pregnancies.Study designAll consecutive women between 24 and 36 weeks gestation with an indication for aspirin use during pregnancy were invited for this study. A survey was used which included two validated questionnaires, the simplified medication adherence questionnaire (SMAQ) and the Beliefs and Behaviour Questionnaire (BBQ).Main outcome measuresTo determine the non-adherence rates of aspirin, and to identify the beliefs and behavior concerning aspirin.ResultsIndications for aspirin use during pregnancy were previous HD, FGR, intrauterine fetal death or current maternal disease. Non-adherence rates according to the SMAQ and BBQ were 46.3% and 21.4% respectively. No differences in demographic background or obstetrical characteristics between adherent and non-adherent women could be demonstrated.ConclusionsAdherence for aspirin in this high-risk population cannot be taken for granted. The non-adherence rates in pregnant women are comparable with the non-adherence rates for aspirin in the non-pregnant population.